Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2165366 | 0.93 | SMN1; SMN2 (0.51) | SMN1; SMN2TSHRUSP2ALDH1A1KDM4E | |
| SCHEMBL2166596 | 0.87 | USP2 (0.60) | SMN1; SMN2TSHRUSP2ALDH1A1KDM4E | |
| SCHEMBL2166042 | 0.87 | RAB9A (0.53) | SMN1; SMN2ALDH1A1KDM4EMAPK1MAPT | |
| SCHEMBL2166325 | 0.84 | KDM4E (0.52) | SMN1; SMN2TSHRALDH1A1KDM4EHTT | |
| SCHEMBL2164157 | 0.83 | L3MBTL1 (0.50) | SMN1; SMN2TSHRALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL2167500 | 0.80 | P2RX7 (0.50) | SMN1; SMN2ALDH1A1L3MBTL1MAPK1MEN1 | |
| SCHEMBL2168162 | 0.80 | LMNA (0.54) | SMN1; SMN2TSHRUSP2ALDH1A1HTT | |
| SCHEMBL2166122 | 0.79 | MEN1 (0.52) | SMN1; SMN2TSHRALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL2166066 | 0.79 | ALDH1A1 (0.51) | SMN1; SMN2TSHRUSP2ALDH1A1KDM4E | |
| SCHEMBL2166025 | 0.78 | DHFR (0.51) | ALDH1A1KDM4EL3MBTL1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069316-B1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2615086-A1 | 2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy | Families of Spinal Muscular Atrophy (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7985755-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2069316-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | Families of Spinal Muscular Atrophy (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008016973-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYT1 | SMN1; SMN2 1/4885TSHR 4604/4885USP2 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.